Podcasts about Psychopharmacology

Play Episode Listen Later Jul 15, 2026 54:15

In this episode, Dr. Andy Cutler is joined by Dr. Roger McIntyre to discuss GLP-1 receptor agonists in psychiatry and why these medications may be relevant beyond weight loss. They explore the emerging role of GLP-1s in metabolic psychiatry, including potential connections with mood disorders, cognition, reward pathways, cardiometabolic health, and psychiatric medication-associated weight gain. Dr. McIntyre also discusses what psychiatric providers should know now, where the evidence is still evolving, and what future research is needed before GLP-1 or incretin-based therapies could be considered part of psychiatric treatment. Roger S. McIntyre, MD, FRCPC, is Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto. He is an internationally recognized expert in mood disorders and psychopharmacology, with published scholarship and presentations exploring the relevance of GLP-1 receptor agonists to psychiatry. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Fall Congress Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today! Membership As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now! Never miss an episode!

new york university head professor toronto md weight loss psychiatry syracuse glp chief medical officers mcintyre cutler pharmacology clinical associate professor psychopharmacology university health network frcpc suny upstate medical university roger mcintyre mood disorders psychopharmacology unit roger s mcintyre andrew j cutler

14 Reasons Why Psychopharmacology Differs in Women, Part 4

women md differs psychopharmacology

Play Episode Listen Later Jul 13, 2026 17:38

Women clear some psychiatric medications more slowly, lose bone density at higher rates, and face greater medical consequences from alcohol and smoking than men. This final episode in a four-part series covers side effects, drug metabolism, drugs of abuse, urine incontinence, and what we do — and don't — know about prescribing for transgender patients.CME: Take the CME Post-Test for this EpisodePublished On: 07/13/2026Duration: 17 minutes, 37 secondsChris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Life After Death? Religion, Occultism, Near-Death Experiences, and the Science of the Dying Mind

TheOccultRejects

Play Episode Listen Later Jul 10, 2026 84:05 Transcription Available

Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Substackhttps://substack.com/@theoccultrejects?r=7auau0&utm_campaign=profile&utm_medium=profile-pageCash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsAssmann, Jan. Death and Salvation in Ancient Egypt. Translated by David Lorton. Cornell University Press, 2005.Ariès, Philippe. The Hour of Our Death. Translated by Helen Weaver. Knopf, 1981.Beard, Mary, John North, and Simon Price. Religions of Rome. 2 vols. Cambridge University Press, 1998.Blackmore, Susan. Dying to Live: Near-Death Experiences. Prometheus Books, 1993.Boyce, Mary. Zoroastrians: Their Religious Beliefs and Practices. Routledge, 1979.Bremmer, Jan N. The Rise and Fall of the Afterlife: The 1995 Read-Tuckwell Lectures at the University of Bristol. Routledge, 2002.Chalmers, David J. “Facing Up to the Problem of Consciousness.” Journal of Consciousness Studies 2, no. 3 (1995): 200–219.Fenwick, Peter, and Elizabeth Fenwick. The Art of Dying: A Journey to Elsewhere. Continuum, 2008.Graf, Fritz, and Sarah Iles Johnston. Ritual Texts for the Afterlife: Orpheus and the Bacchic Gold Tablets. 2nd ed. Routledge, 2013.Greyson, Bruce. After: A Doctor Explores What Near-Death Experiences Reveal about Life and Beyond. St. Martin's Essentials, 2021.Greyson, Bruce. “The Near-Death Experience Scale: Construction, Reliability, and Validity.” Journal of Nervous and Mental Disease 171, no. 6 (1983): 369–375.Griffiths, Roland R., William A. Richards, Una McCann, and Robert Jesse. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology 187, no. 3 (2006): 268–283.Hornung, Erik. The Ancient Egyptian Books of the Afterlife. Translated by David Lorton. Cornell University Press, 1999.Johnston, Sarah Iles. Restless Dead: Encounters between the Living and the Dead in Ancient Greece. University of California Press, 1999.Kerr, Christopher W., et al. “End-of-Life Dreams and Visions: A Longitudinal Study of Hospice Patients' Experiences.” Journal of Palliative Medicine 17, no. 3 (2014): 296–303.Le Goff, Jacques. The Birth of Purgatory. Translated by Arthur Goldhammer. University of Chicago Press, 1984.Moody, Raymond A. Life After Life. Mockingbird Books, 1975.Nahm, Michael, Bruce Greyson, Emily Williams Kelly, and Erlendur Haraldsson. “Terminal Lucidity: A Review and a Case Collection.” Archives of Gerontology and Geriatrics 55, no. 1 (2012): 138–142.Nelson, Kevin R., Michelle Mattingly, Sherman A. Lee, and Frederick A. Schmitt. “Does the Arousal System Contribute to Near Death Experience?” Neurology 66, no. 7 (2006): 1003–1009.Obayashi, Hiroshi, ed. Death and Afterlife: Perspectives of World Religions. Greenwood Press, 1992.Osis, Karlis, and Erlendur Haraldsson. At the Hour of Death. Avon, 1977.Parnia, Sam, et al. “AWAreness during REsuscitation—II: A Multi-Center Study of Consciousness and Awareness in Cardiac Arrest.” Resuscitation 191 (2023).Plato. Phaedo. In Plato: Complete Works. Edited by John M. Cooper. Hackett, 1997.Segal, Alan F. Life After Death: A History of the Afterlife in Western Religion. Doubleday, 2004.Stevenson, Ian. Children Who Remember Previous Lives: A Question of Reincarnation. Rev. ed. McFarland, 2001.Taylor, John H., ed. Journey through the Afterlife: Ancient Egyptian Book of the Dead. Harvard University Press / British Museum Press, 2010.Tucker, Jim B. Life Before Life: A Scientific Investigation of Children's Memories of Previous Lives. St. Martin's Press, 2005.van Gennep, Arnold. The Rites of Passage. Translated by Monika B. Vizedom and Gabrielle L. Caffee. University of Chicago Press, 1960.van Lommel, Pim, Ruud van Wees, Vincent Meyers, and Ingrid Elfferich. “Near-Death Experience in Survivors of Cardiac Arrest: A Prospective Study in the Netherlands.” The Lancet 358, no. 9298 (2001): 2039–2045.Xu, Gang, et al. “Surge of Neurophysiological Coupling and Connectivity of Gamma Oscillations in the Dying Human Brain.” Proceedings of the National Academy of Sciences 120, no. 19 (2023).Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball.

university death children art science fall living religion fun birth rome salvation dead press memories journal experiences survivors rev dying netherlands gang practices consciousness essentials surge sciences afterlife archives edited beard passage moody nervous jacques plato johnston near death experiences fritz reincarnation stevenson neurology national academy kerr purgatory life after death reliability connectivity lancet avon continuum rites griffiths proceedings ancient egypt routledge geriatrics ancient greece graf hackett mcfarland boyce segal cambridge university press knopf chalmers world religions ruud validity wees chicago press cardiac arrest pim california press xu gerontology resuscitation john h fenwick blackmore doubleday occultism palliative medicine hiroshi cornell university press psychopharmacology consciousness studies hornung spiritual significance lommel nahm kevin r bruce greyson bremmer prometheus books life dreams phaedo mental disease osis roland r karlis john north obayashi previous lives western religion simon price hospice patients our death greenwood press william a richards

14 Reasons Why Psychopharmacology Differs in Women, Part 3

women md ob gyn estrogen differs psychopharmacology

Play Episode Listen Later Jul 6, 2026 18:37

Estrogen shapes nearly every neurotransmitter system in the brain, and when it starts to fall, psychiatric disorders often follow. This episode walks through what psychiatrists need to know about the perimenopause: which conditions worsen, which treatments help, and when to call the OB-GYN about hormone replacement therapy.CME: Take the CME Post-Test for this EpisodePublished On: 07/06/2026Duration: 18 minutes, 37 secondsChris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

E285 - Re-release: Eating Disorders, Nutrition, and the Brain with Dr. Cynthia Bulik

Play Episode Listen Later Jul 1, 2026 21:07

Originally released in June 2023, this episode features Dr. Cynthia Bulik in a discussion of eating disorders, nutrition, and the brain. The conversation explores anorexia nervosa, bulimia nervosa, binge eating disorder, ARFID, common misconceptions about eating disorders, and the evolving understanding of how biology, genetics, and environment shape risk, diagnosis, and recovery. Cynthia Bulik, PhD, FAED, is a Distinguished Professor of Eating Disorders in the Department of Psychiatry at the University of North Carolina at Chapel Hill and Professor of Nutrition in the Gillings School of Global Public Health. She is the founding director of the UNC Center of Excellence for Eating Disorders and directs the Centre for Eating Disorders Innovation at Karolinska Institutet, with research focused on the biology, genetics, prevention, and treatment of eating disorders. Fall Congress Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today! Membership As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now! Never miss an episode!

university phd professor brain north carolina nutrition excellence eating disorders psychiatry chapel hill re release distinguished professor cutler karolinska institutet global public health arfid psychopharmacology gillings school unc center

14 Reasons Why Psychopharmacology Differs in Women, Part 2

women adhd md ssris differs psychopharmacology premenstrual

Play Episode Listen Later Jun 29, 2026 23:33

Premenstrual hormones can destabilize mood, worsen ADHD, trigger psychosis, and drive binge eating. This episode walks through the tools to manage hormonal fluctuations in female patients, from SSRIs to overlooked supplements to the lamotrigine-contraceptive drug interaction.CME: Take the CME Post-Test for this EpisodePublished On: 06/23/2026Duration: 23 minutes, 32 secondsChris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychopharmacology Masterclass: Drug Classes, Mechanisms of Action, and What Every Psychologist Needs to Know for Clinical Practice and the

Play Episode Listen Later Jun 24, 2026 17:12 Transcription Available

Psychopharmacology is one of the most heavily tested and clinically consequential domains in professional psychology, covering everything from the neurochemical mechanisms behind antidepressants, antipsychotics, mood stabilizers, and anxiolytics to the pharmacokinetic principles that determine how drugs are absorbed, distributed, metabolized, and eliminated in ways that directly affect treatment outcomes and patient safety. This lecture-style episode breaks down the major drug classes tested on the EPPP and encountered in integrated care settings, including SSRIs, SNRIs, tricyclics, MAOIs, first and second generation antipsychotics, benzodiazepines, and lithium, covering their mechanisms, therapeutic windows, side effect profiles, and the clinical decision-making frameworks psychologists need to consult competently with prescribing professionals. Whether you are preparing for licensure, refreshing your pharmacology knowledge for supervision or consultation, or building the scientific foundation you need to practice in an era of increasingly integrated behavioral health care, this episode delivers the core content in a focused, high-yield format designed to make complex neuroscience and pharmacology accessible and retainable.

science education action psychology medicine medical masterclass drug biology classes medications psychologist physiology mechanisms pharmacology clinical practice ssris psychopharmacology snris maois eppp

14 Reasons Why Psychopharmacology Differs in Women, Part 1

LessWrong Curated Podcast

Play Episode Listen Later Jun 22, 2026 17:32

Women and men respond to psychiatric medications differently. In this first of a four-part series, Chris Aiken and Kellie Newsome walk through why valproate is risky for women, and when it's worth using; why the FDA cut the zolpidem dose in half for female patients, and why SSRIs outperform tricyclics in women with depression. Plus: a sneak preview of DSM-6.CME: Take the CME Post-Test for this EpisodePublished On: 06/22/2026Duration: 27 minutes, 32 secondsChris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

women md fda dsm ssris differs psychopharmacology

"Machinic Psychopharmacology: Do LLMs Self-Medicate?" by Sid Black, Joseph Bloom

Play Episode Listen Later Jun 22, 2026 52:54

Sid Black, Joseph Bloom UK AISI, Model Transparency Team Epistemic status: Most experiments were run over a period of ~2-3 days during a hackathon at UK AISI, and were fairly heavily vibe coded. Expect some of this to be rough around the edges. tl;dr We give two language models (Qwen3-8B and Qwen3-32B) access to “self-steering” tools: a suite of 40 steering vectors as tools they can call to manipulate their own internal states. We make these tools available to the model in various settings: a free-play task, an introspection task, and a maths capabilities task, and observe their behaviour in each. To our knowledge, this is the first work that gives LLMs tool-mediated control over their own internal states. Figure 1: Overview of the experimental setup. The library of 40 steering vectors (top), and the three settings in which we observe the models' behaviour (bottom). We aim to investigate a few high level research questions: RQ1: Which vectors do the models prefer?RQ2: How well can the models introspect on what's happening to them? Can they guess which steering vector is being applied?RQ3: Will the models reach for vectors whilst doing an actual task? If yes: do [...] ---Outline:(00:33) tl;dr[... 24 more sections]--- First published: June 10th, 2026 Source: https://www.lesswrong.com/posts/cNDJuXNZ8MrkPZNzj/machinic-psychopharmacology-do-llms-self-medicate-3 --- Narrated by TYPE III AUDIO. ---Images from the article:

black figure bloom images outline psychopharmacology self medicate

Side Effect Mastery in Psychopharmacology: Rawlings–Thompson A-F Classification, Low Slow Titration & Real-World Management with Dr. Michael Cummings & Dr. Blaire Heath

Psychiatry & Psychotherapy Podcast

Play Episode Listen Later Jun 19, 2026 88:36

Dr. David Puder sits down with psychopharmacology expert Dr. Michael Cummings and Dr. Blaire Heath to discuss Side Effect Mastery in Psychopharmacology. This episode dives deep into the Rawlings–Thompson A-F Classification system for understanding and managing medication side effects, emphasizing low and slow titration strategies to improve tolerability and patient outcomes. They discuss practical, real-world approaches to common challenges, including orthostatic hypotension, excessive sweating (hyperhidrosis from SSRIs/SNRIs), tremor management, alopecia from valproic acid and lithium, anticholinergic burden, and much more. Dr. Cummings shares his insights on receptor dynamics, metabolizer status, bedtime dosing, and when to reconsider diagnosis after treatment failures. By listening to this episode, you can earn 1.25 Psychiatry CME Credits. Link to blog Link to YouTube video

management thompson mastery real world side effects cummings classification rawlings psychopharmacology titration michael cummings

E284 - Nutritional Interventions in Psychiatry: Hype vs. Evidence with Dr. Bhagwan Bahroo

Play Episode Listen Later Jun 17, 2026 46:34

In this episode, Dr. Andy Cutler talks with Dr. Bhagwan Bahroo about nutritional interventions in psychiatry, including diet, supplements, metabolic health, inflammation, and the gut-brain axis. They explore where the evidence is strongest, where hype outpaces the data, and how clinicians can discuss nutritional strategies as adjunctive tools without losing focus on core treatments. Bhagwan A. Bahroo, MD, DLFAPA, is a board-certified psychiatrist in adult, addiction, and forensic psychiatry and an Assistant Professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has extensive clinical experience at Walter Reed National Military Medical Center and has worked in interventional psychiatry, including TMS and esketamine, with an interest in nutrition and its role in mental health. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Fall Congress Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today! Never miss an episode!

new york maryland md hype assistant professor bethesda psychiatry syracuse chief medical officers health sciences nutritional interventions tms clinical associate professor psychopharmacology uniformed services university bhagwan suny upstate medical university andrew j cutler

E283 - PsychopharmaPearls: When Akathisia Looks Like Agitation with Dr. Leslie Citrome

Play Episode Listen Later Jun 3, 2026 29:36

In this episode of PsychopharmaPearls, Dr. Andy Cutler talks with Dr. Leslie Citrome about akathisia, a common but often misdiagnosed antipsychotic side effect that can look like agitation, anxiety, irritability, or worsening psychiatric symptoms. They discuss how to recognize akathisia in clinical practice, distinguish it from true agitation, identify key timing and symptom clues, and avoid common treatment mistakes, including why benztropine is not an appropriate treatment for akathisia. Leslie Citrome, MD, MPH, is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College and an internationally recognized expert in psychopharmacology and clinical trial interpretation. He has authored more than 600 scientific publications and frequently lectures on applying research findings to real-world psychiatric practice. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Fall Congress Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today! Never miss an episode!

new york md psychiatry syracuse mph chief medical officers behavioral sciences clinical professor clinical associate professor agitation psychopharmacology new york medical college suny upstate medical university akathisia andrew j cutler

The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 2

Play Episode Listen Later May 26, 2026 4:30 Transcription Available

Part two In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged from industrial dyes and surgical experiments, how imipramine and lithium were stumbled upon while chasing unrelated ideas, and how these discoveries reshaped our understanding of mental illness. Join us for a fascinating journey through scientific luck, keen observation, and the drugs that freed millions from institutional walls.1

The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 1

science education medicine modern birth biology medications accidental pharmacy physiology serendipity psychosis pharmacology psychopharmacology

Play Episode Listen Later May 25, 2026 3:48 Transcription Available

In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged from industrial dyes and surgical experiments, how imipramine and lithium were stumbled upon while chasing unrelated ideas, and how these discoveries reshaped our understanding of mental illness. Join us for a fascinating journey through scientific luck, keen observation, and the drugs that freed millions from institutional walls.

E282 - 2026 NEI Spring Congress Extended Q&A: Anxiety, Schizophrenia, and Postpartum Mood Disorders with Drs. Strawn, Correll, and Payne

Play Episode Listen Later May 20, 2026 54:39

This episode features extended Q&A sessions addressing unanswered audience questions from select presentations delivered at the 2026 NEI Spring Congress in Kissimmee, Florida: (00:53) From Avoidance to Action: Evidence-based Pathways to Recovery for Difficult-to-Treat Anxiety by Jeffrey R. Strawn, MD, FAACAP (15:21) Perhaps the Grass Is Greener: Why, When, and How to Switch or Combine Treatments for Schizophrenia by Christoph U. Correll, MD (34:42) The Other Side of Motherhood: Advances in the Treatment of Postpartum Mood and Anxiety Disorders by Jennifer L. Payne, MD Fall Congress Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today! Membership As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now! Never miss an episode!

anxiety spring recovery congress md treatments switch difficult membership pathways payne schizophrenia cutler anxiety disorders kissimmee psychopharmacology strawn correll postpartum mood disorders

E281 - ADHD, Hormones, or Aging? Sorting Out Cognitive Complaints in Women with Dr. Neill Epperson

Play Episode Listen Later May 6, 2026 56:26

In this episode, Dr. Andy Cutler speaks with Dr. Neill Epperson about how to evaluate cognitive complaints in women. They discuss how to differentiate between ADHD, hormonal changes (such as perimenopause), mood and anxiety disorders, and age-related cognitive decline. The conversation highlights key clinical clues, including symptom timing and fluctuation, to improve diagnostic accuracy. Practical strategies for assessment and treatment are reviewed to help clinicians make more informed, individualized decisions. C. Neill Epperson, MD, is the Robert Freedman Endowed Professor and Chair of the Department of Psychiatry at the CU Anschutz School of Medicine. She is an internationally recognized expert in women's mental health, with research focused on the effects of hormonal transitions—such as puberty, pregnancy, and menopause—on mood, cognition, and psychiatric disorders. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Never miss an episode!

women new york medicine practical adhd md hormones complaints cognitive psychiatry syracuse chief medical officers neill sorting epperson psychopharmacology suny upstate medical university andrew j cutler

Antidepressant Withdrawal: 50% of Long-Term Users Suffer? Shocking JAMA Study vs Real-World Reality Exposed

Play Episode Listen Later Apr 27, 2026 10:19 Transcription Available

Psychiatrists are clashing over antidepressant withdrawal: clinic data shows up to 50% of long-term SSRI/SRI users face severe symptoms, while a major 2025 JAMA Psychiatry meta-analysis claims they're usually mild and brief. We break down both sides, expose the massive limitations in the studies, and reveal what this means for millions on these drugs.

E280 - PsychopharmaPearls: Managing Rebound Insomnia with Dr. Thomas Schwartz

Play Episode Listen Later Apr 22, 2026 33:45

In this episode, Dr. Andy Cutler speaks with Dr. Thomas Schwartz about insomnia related to antidepressant discontinuation, including how rebound and withdrawal symptoms can emerge when tapering or stopping treatment. They review the underlying mechanisms, clinical risk factors, and how to distinguish discontinuation-related insomnia from relapse of depression or primary sleep disorders. The discussion emphasizes practical, evidence-informed strategies for safely tapering antidepressants and managing sleep disturbance in psychiatric practice. Thomas L. Schwartz, MD, is a Distinguished Teaching Professor at Norton College of Medicine, SUNY Upstate Medical University in Syracuse, New York. He is an award-winning educator deeply involved in medical student and resident training, as well as the development of continuing medical education in psychiatry. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

new york managing medicine md register psychiatry syracuse insomnia rebound chief medical officers psychopharmacology thomas schwartz suny upstate medical university andrew j cutler

Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic

law anxiety medicine addiction ptsd medical ideal controversial psychedelics gamble truth behind ibogaine psychopharmacology miracle cure

Play Episode Listen Later Apr 20, 2026 7:24 Transcription Available

This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological risks. It provides a balanced, evidence-based analysis of ibogaine research, including limitations such as lack of randomized trials, selection bias, and short-term outcome data. Ideal for listeners interested in addiction science, mental health innovation, neuroscience, and the risks and promise of emerging psychedelic therapies.

The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence

business anxiety navigating benefits depression psychology risks limits medications antidepressants pharmacology psychopharmacology messy truth

Play Episode Listen Later Apr 19, 2026 9:05 Transcription Available

Antidepressants demonstrate modest but real benefits for moderate-to-severe depression, with large meta-analyses showing consistent advantages over placebo and meaningful improvements in function for many patients, yet these gains are often smaller than portrayed and heavily influenced by high placebo responses. The evidence base comes with important limitations, including publication bias, short trial durations, industry influence, and challenges in blinding, which can inflate perceived efficacy while understating long-term risks such as sexual dysfunction, emotional blunting, and weight gain reported more frequently in real-world surveys. Navigating antidepressants requires pragmatic humility: they are a valuable tool for the right person at the right time when used with careful monitoring, deprescribing when appropriate, and combined with therapy and lifestyle changes, rather than as a one-size-fits-all solution or something to fear outright.

Why One ADHD Medication Hits Kids So Differently — And How Genetics Can Help

kids adhd hits medications genetics psychopharmacology adhd medication

Play Episode Listen Later Apr 11, 2026 1:38 Transcription Available

E279 - Sleep in Bipolar Disorder: Clinical Insights with Dr. Holly Swartz

Play Episode Listen Later Apr 8, 2026 50:14

In this episode, Dr. Andy Cutler speaks with Dr. Holly Swartz about the critical role of sleep and circadian rhythms in bipolar disorder, including how sleep disturbance can function as both a symptom and trigger of mood episodes. They discuss how clinicians can better assess sleep to identify early warning signs of relapse, along with practical strategies for intervention, including applying principles of Interpersonal and Social Rhythm Therapy (IPSRT), choosing between behavioral and pharmacologic treatments for insomnia, and avoiding sleep medications that may destabilize mood. The episode offers a clinically focused approach to improving relapse prevention through better sleep management. Holly A. Swartz, MD, is Professor of Psychiatry at the University of Pittsburgh, Director of the Center for Advanced Psychotherapy, and Medical Director of the Depression and Manic Depression Prevention Program. An internationally recognized expert in bipolar disorder treatment, she is President of the International Society for Bipolar Disorders and known for advancing Interpersonal and Social Rhythm Therapy (IPSRT), an evidence-based approach targeting sleep, circadian rhythms, and mood stabilization to prevent relapse. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources The Social Rhythm Therapy Workbook for Bipolar Disorder Bipolar II Disorder Interpersonal and Social Rhythm Therapy – ipsrt.org Depression and Bipolar Support Alliance – dbsalliance.org Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

E278 - Re-release: Autism Spectrum Disorder and Comorbidities with Dr. Robyn Thom

adhd md autism assistant professor disorders psychiatry harvard medical school re release thom asd autism spectrum disorder comorbidities psychopharmacology

Play Episode Listen Later Mar 25, 2026 36:57

In this revisited episode, Dr. Robyn Thom discusses autism spectrum disorder (ASD) and the psychiatric comorbidities that frequently accompany it. She reviews how ASD is diagnosed, the core domains of social communication differences and restricted or repetitive behaviors, and why treatment often focuses on co-occurring conditions such as anxiety, ADHD, sleep disorders, and agitation. Dr. Thom also shares practical strategies for evaluating agitation, distinguishing overlapping symptoms, and selecting behavioral and pharmacologic interventions to support patients with ASD across the lifespan. Robyn Thom, MD, is an Assistant Professor of Psychiatry at Harvard Medical School and a staff psychiatrist at the Massachusetts General Hospital Lurie Center for Autism. She specializes in treating children and adults with autism spectrum disorder and other neurodevelopmental conditions, with clinical and research interests in psychiatric comorbidities, anxiety, and mood disorders. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

Cannabis, Multitasking, Doppelpenis

Wissensnachrichten - Deutschlandfunk Nova

Play Episode Listen Later Mar 12, 2026 5:26

Die Themen in den Wissensnachrichten: +++ Cannabis hat schlechten Einfluss aufs Gedächtnis +++ Echtes Multitasking gibt es gar nicht +++ Sexstellung von Eintagsfliegen im CT beobachtet +++**********Weiterführende Quellen zu dieser Folge:Studie zu Cannabis und Gedächtnis, Journal of Psychopharmacology, Feb. 2026Studie zu Multitasking, Quarterly Journal of Experimental Psychology, Nov. 2025Studie zum Sex von Eintagsfliegen, Insect Systematics and Diversity, März 2026Studie zur Vielfalt im Denken der Chatbots, Trends in Cognitive Sciences, 11. März 2026Studie zu Stadt- und Landameisen, Urban Ecosystems, Jan. 2026Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

tiktok sex diversity journal cannabis ihr stadt einfluss denken chatbots ged vielfalt multitasking quellen die themen cognitive science experimental psychology psychopharmacology quarterly journal eintagsfliegen

E277 - Shaping Recovery: Early Psychosis Outcomes and Engagement with Dr. Robert Cotes

The Trauma Therapist | Podcast with Guy Macpherson, PhD | Inspiring interviews with thought-leaders in the field of trauma.

Play Episode Listen Later Mar 11, 2026 57:35

In this episode, Dr. Andy Cutler talks with Dr. Robert Cotes about optimizing outcomes in early psychosis and why the first episode is a critical window for intervention. They discuss the impact of duration of untreated psychosis, recovery trajectories after a first episode, and what to measure beyond symptom reduction—including functional outcomes, cognition, and relapse risk. The conversation also highlights strategies for engaging young adults and families in coordinated specialty care, early identification of clinical high risk for psychosis, and innovations aimed at improving long-term recovery. Robert O. Cotes, MD, is Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatry at Grady Health System in Atlanta. He directs the Clinical and Research Program for Psychosis at Grady, which includes Project ARROW, a coordinated specialty care program for young people with early psychosis, and a specialized clozapine clinic for treatment-resistant schizophrenia. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

Owning Your Story with Dr. Andrea Gleim

Play Episode Listen Later Mar 6, 2026 31:07 Transcription Available

Dr. Andrea Gleim is a bilingual psychologist, empowerment coach, and speaker with over 10 years of experience helping high-achieving professionals navigate identity, leadership, and life transitions.She is the founder of Mindfully Mine Counseling Center and an adjunct professor at Felician University, where she has taught courses such as Psychopharmacology, Theories of Personality Disorders, and Introduction to Counseling.A proud Salvadorian and Puerto Rican Latina and first-generation college graduate, Dr. Gleim empowers clients to own their stories without code-switching. Her work blends psychology, mindfulness, cultural identity, and coaching to address imposter syndrome, career reinvention, In This EpisodeLinkedIn InstagramAndrea's websiteBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-trauma-therapist--5739761/support.You can learn more about what I do here:The Trauma Therapist Newsletter: celebrates the people and voices in the mental health profession. And it's free! Check it out here: https://bit.ly/4jGBeSa———If you'd like to support The Trauma Therapist Podcast and the work I do you can do that here with a monthly donation of $5, $7, or $10: Donate to The Trauma Therapist Podcast.Click here to join my email list and receive podcast updates and other news.Thank you to our Sponsors:Jane App - use code GUY1MO at https://jane.appArizona Trauma Institute at https://aztrauma.org/

counseling theories personality disorders owning your story psychopharmacology salvadorians

E276 - PsychopharmaPearls: Choosing Ketamine Treatment with Dr. Lisa Harding

Illuminated with Jennifer Wallace

Play Episode Listen Later Feb 25, 2026 32:39

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient. Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut. Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080 McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251 Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

new york md treatments connecticut iv yale university psychiatry syracuse implementation new haven harding ketamine nei cns cutler tms clinical associate professor assistant clinical professor ect mood disorders synthesizing psychopharmacology jama psychiatry consensus statement suny upstate medical university esketamine am j psychiatry andrew j cutler

How Psychedelic Experiences Support Growth When the Nervous System Is Prepared and Integrated

Play Episode Listen Later Feb 23, 2026 54:52

Psychedelics are having a cultural moment. Research is promising. Stories of healing are everywhere. But here's the truth: these experiences aren't magic cures. And they aren't right for every nervous system at every time. In this episode, Elisabeth Kristof and Jennifer Wallace slow the conversation down. Instead of asking, "Do psychedelics heal trauma?" They explore a more grounded question: What becomes possible when psychedelic or peak somatic experiences are approached through the lens of nervous system safety, preparation, and integration? If you've been curious about psychedelics, already had experiences, or feel unsure whether they're right for you, this episode offers nuance, research, and deep nervous system perspective. Because post-traumatic growth isn't about becoming someone new. It's about becoming more available to the life that's already waiting for you. Topic Covered Why psychedelics may reorganize meaning, not just reduce symptoms How trauma fragments narrative and how safety allows integration The science of psychological flexibility and why it predicts long-term outcomes What "somatic journeying" is and why it can feel disorienting The importance of preparation, titration, and facilitator trust Why intensity does not equal healing Psychedelics vs antidepressants in research on connectedness Default Mode Network (DMN), identity rigidity, and belief updating Why creativity often emerges when survival softens The risks of over-reliance and "chasing the medicine" Why discernment and self-trust matter more than hype Chapters 00:00 – Psychedelics Aren't Magic Cures  03:00 – Meaning-Making & Narrative Reorganization  08:58 – Psychological Flexibility & Emotional Capacity  17:00 – Preparation, Somatic Journeying & Integration  23:29 – Connectedness & Relational Repair  34:33 – Identity, Neuro Tags & the Default Mode Network  41:03 – Creativity as a Byproduct of Safety  48:14 – Discernment, Industry Hype & Self-Trust Calls to Action: Neurosomatic Intelligence is now enrolling : https://neurosomaticintelligence.com/nsi-certification Sacred Synapse: an educational YouTube channel founded by Jennifer Wallace that explores nervous system regulation, applied neuroscience, consciousness, and psychedelic preparation and integration through Neurosomatic Intelligence. Wayfinder Journal: Track nervous system patterns and support preparation and integration through Neurosomatic Intelligence. FREE 1 Year Supply of Vitamin D + 5 Travel Packs from Athletic Greens when you use my exclusive offer: https://www.drinkag1.com/rewired Learn to work with Boundaries at the level of the body and nervous system at https://www.boundaryrewire.com Get a two-week free trial of neurosomatic training at https://rewiretrial.com Sources: Amada, N., et al. "The Transformative Potential of Psychedelic Experiences: A Qualitative Analysis of Meaning-Making and Narrative Reorganization." Journal of Consciousness Studies, vol. 27, no. 7–8, 2020, pp. 122–150. Carhart-Harris, Robin L., et al. "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin." Proceedings of the National Academy of Sciences, vol. 109, no. 6, 2012, pp. 2138–2143. Carhart-Harris, Robin L., et al. "The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs." Frontiers in Human Neuroscience, vol. 8, 2014, article 20. Carhart-Harris, Robin L., et al. "Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up." Psychopharmacology, vol. 235, no. 2, 2018, pp. 399–408. Davis, Alan K., Roland R. Griffiths, and Frederick S. Barrett. "Psychological Flexibility Mediates the Relations between Acute Psychedelic Effects and Subjective Decreases in Depression and Anxiety." Journal of Contextual Behavioral Science, vol. 15, 2020, pp. 39–45. Davis, Alan K., et al. "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial." JAMA Psychiatry, vol. 78, no. 5, 2021, pp. 481–489. Erritzoe, David, et al. "Effects of Psilocybin Therapy versus Escitalopram on Depression and Emotional Connectedness in Major Depressive Disorder." The New England Journal of Medicine, vol. 384, 2021, pp. 1402–1411. Griffiths, Roland R., et al. "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial." Journal of Psychopharmacology, vol. 30, no. 12, 2016, pp. 1181–1197. MacLean, Katherine A., Matthew W. Johnson, and Roland R. Griffiths. "Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness." Journal of Psychopharmacology, vol. 25, no. 11, 2011, pp. 1453–1461. Watts, Rosalind, et al. "Patients' Accounts of Increased 'Connectedness' and 'Acceptance' after Psilocybin for Treatment-Resistant Depression." Journal of Humanistic Psychology, vol. 57, no. 5, 2017, pp. 520–564. Weiss, B., et al. "Associations between Naturalistic Psychedelic Use, Psychological Insight, and Changes in Social Connectedness and Personality." Frontiers in Psychology, vol. 12, 2021, article 667987. Disclaimer: Trauma Rewired podcast is intended to educate and inform but does not constitute medical, psychological or other professional advice or services. Always consult a qualified medical professional about your specific circumstances before making any decisions based on what you hear. We share our experiences, explore trauma, physical reactions, mental health and disease. If you become distressed by our content, please stop listening and seek professional support when needed. Do not continue to listen if the conversations are having a negative impact on your health and well-being. If you or someone you know is struggling with their mental health, or in mental health crisis and you are in the United States you can 988 Suicide and Crisis Lifeline. If someone's life is in danger, immediately call 911. We do our best to stay current in research, but older episodes are always available. We don't warrant or guarantee that this podcast contains complete, accurate or up-to-date information. It's very important to talk to a medical professional about your individual needs, as we aren't responsible for any actions you take based on the information you hear in this podcast. We invite guests onto the podcast. Please note that we don't verify the accuracy of their statements. Our organization does not endorse third-party content and the views of our guests do not necessarily represent the views of our organization. We talk about general neuro-science and nervous system health, but you are unique. These are conversations for a wide audience. They are general recommendations and you are always advised to seek personal care for your unique outputs, trauma and needs. We are not doctors or licensed medical professionals. We are certified neuro-somatic practitioners and nervous system health/embodiment coaches. We are not your doctor or medical professional and do not know you and your unique nervous system. This podcast is not a replacement for working with a professional. The BrainBased.com site and RewireTrial.com is a membership site for general nervous system health, somatic processing and stress processing. It is not a substitute for medical care or the appropriate solution for anyone in a mental health crisis. Any examples mentioned in this podcast are for illustration purposes only. If they are based on real events, names have been changed to protect the identities of those involved. We've done our best to ensure our podcast respects the intellectual property rights of others, however if you have an issue with our content, please let us know by emailing us at traumarewired@gmail.com. All rights in our content are reserved.

united states stories growth anxiety research identity depression psychology medicine creativity safety boundaries journal patients suicide effects preparation personality prepared chapters psychedelics sciences discernment relations determined accounts watts weiss vitamin d nervous system increases integrated national academy frontiers associations openness psilocybin griffiths proceedings maclean new england journal athletic greens crisis lifeline byproducts major depressive disorder psychedelic experiences psychopharmacology default mode network psychedelic drugs consciousness studies travel packs treatment resistant depression humanistic psychology jama psychiatry jennifer wallace human neuroscience escitalopram contextual behavioral science roland r alan k robin l matthew w johnson roland r griffiths

E275 - Busting Myths About ADHD Medications with Dr. Tim Wilens

Maudsley Learning Podcast

Play Episode Listen Later Feb 11, 2026 55:32

In this episode, Dr. Andy Cutler talks with Dr. Tim Wilens about enduring myths surrounding ADHD diagnosis and treatment, beginning with why misconceptions about overdiagnosis and misuse continue to shape clinical hesitation. They explore common misunderstandings about ADHD medications—including stimulants versus non-stimulants, concerns about diversion, personality changes, and long-term safety—and contrast stigma-driven narratives with the clinical evidence. The conversation equips clinicians with practical, evidence-based strategies to address patient fears, counter misinformation, and make thoughtful, individualized treatment decisions. Timothy Wilens, MD, is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders, embedded health care models, and the pharmacotherapy of ADHD across the lifespan. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

new york child adhd md medications psychiatry syracuse harvard medical school chief medical officers massachusetts general hospital clinical associate professor addiction medicine busting myths adolescent psychiatry psychopharmacology suny upstate medical university andrew j cutler

E161 | How do Psychedelics Help with Depression? (Professor Emma Robinson)

Play Episode Listen Later Feb 5, 2026 48:03 Transcription Available

Professor Emma Robinson is Professor of Psychopharmacology at the University of Bristol. Professor Robinson conducts research with rodents, which can help us to better understand how emotions get formed by the brain and how novel fast-acting antidepressants like ketamine and psilocybin (aka the active ingredient of magic mushrooms) could cause antidepressant effects. We discuss how animal research can help us understand human emotions and very human conditions like depression, and why psychedelics might work to treat it.Interviewed by Dr. Anya Borissova - Give feedback here - thinkingmindpodcast@gmail.com Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast Tiktok - @thinking.mind.podcast Check out The Thinking Mind Blog on Substack: https://substack.com/home/post/p-183600902If you would like to invite Alex to speak at your organisation please email alexcurmitherapy@gmail.com with "Speaking Enquiry" in the subject line.Alex is not currently taking on new psychotherapy clients, if you are interested in working with Alex for focused behaviour change coaching , you can email - alexcurmitherapy@gmail.com with "Coaching" in the subject line. Give feedback here - thinkingmindpodcast@gmail.com Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast

university tiktok interview coaching professor depression substack psychedelics psychopharmacology professor robinson emma robinson

Dr David Erritzoe

The Mid•Point with Gabby Logan

Play Episode Listen Later Feb 4, 2026 49:54

Today we speak to David Erritzoe (Clin Associate Professor in Psychopharmacology & Psychiatry) .A leading researcher in the science of psychedelics, addiction, and mental health, David joins us to unpack what's actually happening in the brain when patterns break, beliefs loosen, and change becomes possible. Together, we explore the tension between biology and meaning, evidence and experience — and what modern neuroscience can (and can't) tell us about transformation.This conversation sits right at the heart of the journey: a moment to question assumptions, re-examine what we think we know about the mind, and consider how altered states — whether clinical, chemical, or contemplative — might reshape the stories we tell about ourselves.David is a highly cited scientist (top 0.1% globally in 2025, Clarivate), and in 2025 received Imperial's President Award for Excellence in Research, and his team has received several additional awards in recent years. David and his team have been awarded competitive grant & fellowship funding, hereunder from MRC/UKRI, NIHR and Welcome Trust. David has published 150+ scientic papers, contributed to 7 books (incl author of 6 book chapters), an per Dec 2025 has a Scopus h-index of 54 and 19k+ citations. Hosted on Acast. See acast.com/privacy for more information.

research excellence acast psychiatry imperial psychopharmacology scopus nihr clarivate

E274 - Busting Myths About Antipsychotics with Dr. Jonathan Meyer

anxiety depression trauma scary psychiatry psychotherapy consultation sleep apnea google sheets psychopharmacology

Play Episode Listen Later Jan 28, 2026 46:10

In this episode, Dr. Andy Cutler speaks with Dr. Jonathan Meyer to dispel common myths about antipsychotic treatment, from concerns about sedation, personality change, and brain effects to misunderstandings about safety, long-acting injectables, and clozapine. The discussion focuses on what the evidence actually shows about efficacy, risk, and recovery, and how clinicians can communicate more clearly and confidently with patients and families. Jonathan Meyer, MD, DLFAPA, is a Voluntary Clinical Professor of Psychiatry at the University of California, San Diego. He serves as a Senior Academic Advisor to the California Department of State Hospitals, is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center, and has published extensively on psychopharmacology, including co-authoring The Clozapine Handbook, The Clinical Use of Antipsychotic Plasma Levels, and The Lithium Handbook with Dr. Stephen Stahl. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 Register today at nei.global/spring Never miss an episode!

new york university california san diego md psychiatry syracuse chief medical officers california department clinical associate professor busting myths psychopharmacology antipsychotics suny upstate medical university clinical use jonathan meyer andrew j cutler

The Scary Med List-- A Case Consultation with Dr. H

Back from the Abyss

Play Episode Listen Later Jan 23, 2026 22:57

Dr. H dives deep into a patient's scary, confusing, and ill-advised list of psych meds to illustrate some deeper truths and lessons about psychopharmacology and the med management model of psychiatry.Support the show! https://www.buzzsprout.com/396871/supportExplore the full BFTA Content Catalog:A listener-built, human-curated index of every Back From The Abyss episode to help you find themes, topics, and episode formats of interest.Best viewed on a laptop or desktop (not mobile).Content Catalog (in Google Sheets): https://bftapod.short.gy/indexBFTA episode recommendations/Podcast pagehttps://www.craigheacockmd.com/podcast-page/Support the show

Psychedelic Assisted Psychotherapy and Integration Pt 1 w/ Dr. Aryan Sarparast and Will Lucas

Psychiatry Explored

Play Episode Listen Later Jan 23, 2026 91:26

Join us as we begin our two part discussion of Psychedelic Assisted Psychotherapy and Integration with Dr. Arayan Sarparast of the OHSU Psilocybin Education & Assessment Collaborative for Excellence (PEACE) Clinic and clinical research coordinator Will Lucas. This episode focuses primarily on counseling patients interested in Psychedelic Assisted Psychotherapy and harm reduction strategies when working with patients that have presented to the hospital with altered mental status after ingesting Psychedelic substances. We also discuss medico-legal issues surrounding psilocybin, primarily in the state of Oregon. Stay tuned for part 2 in which we will further dive into integration and psychotherapy after psychedelic experiences. Additional learning materials and resources for this episode can be found at: About Oregon Psilocybin Services:⁠https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx⁠Kelan L. Thomas, B.E.S. Robert Jesse, Nicky J. Mehtani, Jennifer M. Mitchell & Brian T. Anderson (2023): Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics, Journal of Psychoactive Drugs, DOI: 10.1080/02791072.2023.2201244Bathje GJ, Majeski E and Kudowor M (2022) Psychedelic integration: An analysis of the concept and its practice.Front. Psychol. 13:824077. doi: 10.3389/fpsyg.2022.824077Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268-1278.For any questions and feedback, please contact us at psychiatryexplored@gmail.com.

oregon journal front integration survey psychedelics psychotherapy acute assisted griffiths doi maclean doses bradstreet psychopharmacology psychol psychoactive drugs will lucas

The Behavioral Health Blueprint with Jimmie Williamson

LTC University Podcast

Play Episode Listen Later Jan 14, 2026 42:24

In this episode of Your Health University, Jamie sits down with Dr. Jimmie Williamson, Chief Behavioral Health Officer at Your Health, to break down why behavioral health belongs inside primary care—not outside it. Jimmie explains how telehealth lowered stigma, how mental health diagnoses (“F codes”) often correlate with frequent ER use, and why Your Health moved from intuition to data-driven referral models using tools like Power BI. They also map the full behavioral health ecosystem—from psych nurse practitioners to therapists to the psych pharmacist—and clarify when and how teams should refer patients for the right level of support. The takeaway is simple: earlier behavioral health intervention can improve lives, reduce hospital visits, and strengthen value-based care outcomes system-wide. www.YourHealth.Org

E273 - Busting Myths About Antidepressants with Dr. Jeffrey Strawn

Play Episode Listen Later Jan 14, 2026 53:09

In this episode, Dr. Andy Cutler and Dr. Jeff Strawn unpack common misconceptions that complicate real-world use of antidepressants. They review evidence on efficacy, suicidality risk, mechanisms, and early side effects, and discuss how to navigate hesitancy and misinformation. The conversation also addresses when to start medication, how to balance caution with timely intervention in youth, and practical ways to strengthen trust and therapeutic alliance. Jeffrey R. Strawn, MD, FAACAP, is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Zhang K et al. Functional connectivity predicting transdiagnostic treatment outcomes in internalizing psychopathologies. JAMA Netw Open 2025;8(9):e2530008. doi: 10.1001/jamanetworkopen.2025.30008 Lagerberg T et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022;47(4):817-23. doi: 10.1038/s41386-021-01179-z Never miss an episode!

E272 - Our Most Downloaded Episode of 2025: Borderline Personality Disorder with Dr. Carla Sharp

Psychopharmacology and Psychiatry Updates

Play Episode Listen Later Dec 31, 2025 60:41

As 2025 comes to an end, we revisit our most downloaded episode of the year. Join Dr. Andy Cutler and Dr. Carla Sharp as they explore the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also highlights recent updates to the APA's BPD guidelines and what they mean for clinical practice. Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Never miss an episode!

Postpartum Psychopharmacology: Breastfeeding and Bipolar Disorder

Play Episode Listen Later Dec 27, 2025 8:48

In this episode, we explore pharmacologic strategies for postpartum psychosis with insights from Dr. Lauren Osborne, focusing on a critical clinical question: Can we safely use mood stabilizers like lithium in breastfeeding mothers with bipolar disorder? Discover evidence-based guidance for navigating this high-stakes decision when maternal mental health hangs in the balance. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Postpartum Psychosis: Pharmacologic Strategies

discover disorders earn postpartum breastfeeding bipolar disorder psychopharmacology

Pearls in Primary Care Psychopharmacology

MedicalMissions.com Podcast

Play Episode Listen Later Dec 24, 2025

Dive into decision support tools and management options for primary care mental health conditions that often stump the primary care clinician.

women children mental health dive medical psychiatry pediatrics pearls internal medicine surgical midwife nurse practitioners primary care family medicine physician assistants psychopharmacology advanced practice

Episode 259: DMT Aliens

UFO...No!

Play Episode Listen Later Dec 22, 2025 73:35

In this episode I compare DMT experiences and some of the most famous alien abduction cases on record like the Betty and Barney Hill case. The similarities are fascinating!Thanks to the TIN FOIL MULISHAExclusive episodes on Patreon https://www.patreon.com/c/ufonopodcastJoin the Tin Foil Mulisha Discord:⁠ https://discord.gg/PQyaJzkt4Y⁠Paypal Donation ⁠https://www.paypal.com/ncp/payment/Y6WRSW9F2JBSCStripe Donation https://buy.stripe.com/aFa6oGeiXamjdlW39HgUM00Buy Merch⁠ https://ufono.dashery.com/ | https://ufono-podcast.creator-spring.com/Buy Mushrooms⁠ https://www.schedule35.co/us/ (Code: U1173687US240607)⁠Email: Iwant2believe115@gmail.comFollow: Facebook | Twitter | Twitch | Kick | RumbleStrassman, R. (2001). DMT: The Spirit Molecule. (Research summary via OPEN Foundation)Davis, A.K. et al. (2020). “Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine.” J. Psychopharmacology, 34(9), 1008-1020.Taub, B. (2020). “People Seeing Strange Entities When Taking DMT Could Be the Source of ‘Alien Abductions'.” IFLScience (reporting on Davis et al. 2020 survey).Magee, T. (2023). “DMT Users Are Using AI to Draw the Strange Beings They Meet While Tripping.” Vice (interview with DMT researchers).Nichols, D. et al. (2023). “Why N,N-Dimethyltryptamine (DMT) matters: unique features and therapeutic potential beyond classical psychedelics.” *Front. Psychiatry, 15:*1485337pmc.ncbi.nlm.nih.govWikipedia contributors. “Perspectives on the alien abduction phenomenon – Drug-induced hallucinations.” Wikipedia (summarizing Strassman's findings).

research aliens front wikipedia draw perspectives drug vice survey psychiatry nichols dmt alien abduction magee barney hill taub psychopharmacology dmt the spirit molecule strassman iflscience

E271 - A Look Back at This Year in Psychopharmacology with Dr. Roger McIntyre

Play Episode Listen Later Dec 17, 2025 44:33

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry. Roger McIntyre, MD, FRCPC, is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Thanarajah ES et al. Soft drink consumption and depression mediated by gut microbiome alterations. JAMA Psychiatry 2025;82(11):1095–1102. doi:10.1001/jamapsychiatry.2025.2579 Durgam S et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry 2025;86(4):25m15848. doi: 10.4088/JCP.25m15848 Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789 Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025;645:712–21. doi: 10.1038/s41586-025-09335-x Never miss an episode!

new york university nature professor toronto md alzheimer's disease psychiatry syracuse chief medical officers mcintyre pharmacology clinical associate professor psychopharmacology jcp frcpc jama psychiatry suny upstate medical university roger mcintyre andrew j cutler

Warum trinken Menschen - die Drunk-Hypothese

Betreutes Fühlen

Play Episode Listen Later Dec 8, 2025 62:27 Transcription Available

Geht uns Menschen etwas verloren, wenn wir weniger Alkohol trinken? Alkohol ist schlimm. Schädlich für die Gesundheit. Ursache für Gewalt. Es gibt so viel Kritik an Alkohol. Und dann kommt ein berühmter Psychologieprofessor und fragt sich besorgt, ob seine Studierenden mittlerweile zu wenig Alkohol trinken. Dahinter steckt die Drunk-Hypothese. Nie gehört? Dann Glühwein weg und BF an. Fühlt euch gut betreut Leon & Atze Instagram: https://www.instagram.com/leonwindscheid/ https://www.instagram.com/atzeschroeder_offiziell/ Mehr zu unseren Werbepartnern findet ihr hier: https://linktr.ee/betreutesfuehlen Tickets: Atze: https://www.atzeschroeder.de/#termine Leon: https://leonwindscheid.de/tour/ Vorverkauf 2026: https://betreutes-fuehlen.ticket.io/ Quellen: Inzlicht, M. Should PhD students drink more?. Theor Soc (2025). Das Buch Drunk ist von Edward Slingerland Zahlen in Deutschland: Bundesministerium für Gesundheit. (2025, 24. September). Alkohol. https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/alkohol.html Wang, J., Jiang, L., & Sun, H. (2021). Early evidence for beer drinking in a 9000-year-old platform mound in southern China. PLoS One. Die Drunk-Hypothese auf dem Prüfstand: Hrnčíř, V., Chira, A.M. & Gray, R.D. Did alcohol facilitate the evolution of complex societies?. Humanit Soc Sci Commu. (2025). Drunk Hypothese einfach auf Deutsch zusammengefasst: https://www.mpg.de/25056851/0715-evan-alkohol-und-der-aufstieg-komplexer-gesellschaften-150495-x Alkohol und Stimmung: Dora, Jonas, et al. "The daily association between affect and alcohol use: A meta-analysis of individual participant data." Psychological Bulletin. Sayette, M. A., Creswell, K. G., Dimoff, J. D., Fairbairn, C. E., Cohn, J. F., Heckman, B. W., ... & Moreland, R. L. (2012). Alcohol and group formation: A multimodal investigation of the effects of alcohol on emotion and social bonding. Psychological science. Creswell, K. G., Wright, A. G., Sayette, M. A., Girard, J. M., Lyons, G., & Smyth, J. M. (2024). The Effects of Alcohol in Groups of Heavy-Drinking Young Adults: A Multimodal Investigation of Alcohol Responses in a Laboratory Social Setting. Clinical Psychological Science. Alkohol und Niederländisch sprechen: Renner, F., Kersbergen, I., Field, M., & Werthmann, J. (2018). Dutch courage? Effects of acute alcohol consumption on self-ratings and observer ratings of foreign language skills. Journal of Psychopharmacology. Das Eisberg Modell: Lindenmeyer, J. (2013). Ich bin kein Alkoholiker!: Ambulante Psychotherapie bei Alkoholproblemen-Mit Online-Material. Springer-Verlag. Orth, B., Spille-Merkel, C. & Nitzsche, A. (2025). Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2023. Substanzkonsum und Internetnutzung im Jahr 2023 und Trends. Köln: Bundeszentrale für gesundheitliche Aufklärung. Redaktion: Leon Windscheid Produktion: Murmel Productions

E270 - (CME) Complex Depression: Treating Beyond the Standard Algorithm

Play Episode Listen Later Dec 3, 2025 60:41

In this CME episode, Dr. Andy Cutler talks with Drs. Stephen Stahl and Roger McIntyre about recognizing and managing complex depression, particularly major depressive episodes with mixed or anxious features. They discuss how these specifiers affect diagnosis, symptom severity, and treatment response, and explore evidence-based strategies for optimizing outcomes through individualized and adjunctive approaches. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e270-cme Never miss an episode!

depression complex treating algorithms drs nei cme psychopharmacology cme/ce roger mcintyre

E269 - (CME) Navigating Complexity: Personalized Treatment Approaches Across the Stages of Bipolar I Disorder